Dr. James Freeman is a clinical cardiac electrophysiologist with a focus on the ablation of complex arrhythmias (supraventricular tachycardias, atrial fibrillation and flutter, and ventricular tachycardia), and left atrial appendage occlusion.
He presently serves as Director of the Cardiac Electrophysiology Laboratories for Yale New Haven Health and as the Director of the Yale Atrial Fibrillation Program. Dr. Freeman has additional interests in implantable cardiac devices for cardiac arrhythmias and heart failure, including pacemakers, implantable cardioverter defibrillators (ICDs), and cardiac resynchronization therapy (CRT) devices.
A graduate of Johns Hopkins University School of Medicine, Dr. Freeman has also earned a master’s of public health with a concentration in biostatistics and epidemiology from Johns Hopkins and a master’s in health services research from Stanford. He has published extensively on topics of comparative effectiveness, cost effectiveness, and clinical outcomes with cardiac arrhythmias. With funding from the National Institutes of Health and the American College of Cardiology, Dr. Freeman is researching the safety and effectiveness of therapies for the prevention and treatment of atrial fibrillation, ventricular fibrillation/tachycardia, sudden cardiac death, stroke, and heart failure.
Dr. Freeman has participated in the Heart Rhythm Society New Leaders in Electrophysiology Leadership Program and is a fellow of the American College of Cardiology.